Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Ltd. (TEVA) is a global leader in generic medicines and biosimilars, delivering cost-effective healthcare solutions across 60+ countries. This dedicated news hub provides investors and professionals with verified updates on Teva’s strategic initiatives, regulatory milestones, and market developments.
Find official press releases, earnings reports, and analysis covering Teva’s core operations in generics manufacturing, innovative therapies, and active pharmaceutical ingredients (APIs). Our curated feed includes updates on FDA approvals, partnership announcements, patent developments, and sustainability initiatives impacting the pharmaceutical sector.
Bookmark this page to monitor Teva’s progress in biosimilar innovation, supply chain expansions, and responses to industry trends. All content is sourced from verified channels to support data-driven decisions in the evolving healthcare landscape.
Rhea-AI Summary
Teva Pharmaceutical announced the pricing and early acceptance results of its debt tender offers for various series of outstanding notes. The company will purchase notes across three pools with tender caps of $1.55B, $350M, and $400M respectively. Notes with Acceptance Priority Level 4 will be accepted in full, while those with levels 1, 2, and 5 will be subject to proration factors of 60.74999%, 39.4586%, and 36.663%. Notes with Priority Levels 3 and 6 will not be accepted. The settlement is expected on June 5, 2025, with holders receiving the Total Consideration including Early Tender Premium. The offers were supported by Teva's recent $2.3B senior notes offering on May 28, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical announced early tender results for its debt tender offers, including increases to tender pool caps and total maximum amount. The company increased Pool 2 Tender Cap from $250M to $350M, Pool 3 Tender Cap from $200M to $400M, and Total Maximum Amount from $2.25B to $2.3B. The tender offers cover multiple series of senior notes with various interest rates and maturities. Teva expects to accept notes worth approximately $2.3B for purchase, with settlement scheduled for June 5, 2025. The tender offers are funded through proceeds from a recent public offering of debt securities and cash on hand. This move is part of Teva's strategy to manage and optimize its debt capital structure and extend its debt maturity profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
-
Rhea-AI Summary
Teva Pharmaceuticals revealed concerning findings about tardive dyskinesia (TD) treatment in long-term care facilities. The study showed that over 50% of LTC residents with TD don't receive standard care treatment, and 25% receive no treatment at all. Among residents on antipsychotic drugs, 5.6% were diagnosed with extrapyramidal syndrome while only 1.1% received specific TD diagnosis. The research, analyzing ~700,000 residents on antipsychotic drugs and ~35,000 on Reglan, found mood disorders as the most common underlying condition (68% and 54% respectively). Common comorbidities included dementia, chronic pulmonary disease, and congestive heart failure. Less than half of TD patients received the recommended VMAT2 inhibitor treatment, with most receiving non-FDA approved treatments like benztropine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
Rhea-AI Summary
Teva Pharmaceuticals presented significant data for its schizophrenia treatment portfolio at the 2025 Psych Congress Elevate Annual Meeting. Real-world studies of UZEDY (risperidone) showed superior outcomes compared to oral treatments, including lower relapse rates (9.0% vs 15.4-16.8%), better adherence (71.3% vs 52.8%), and reduced healthcare costs ($18,796 vs $26,376). UZEDY patients also experienced fewer hospital visits and shorter stays. Additionally, Teva's investigational drug TEV-'749 (olanzapine) demonstrated promising Phase 3 SOLARIS trial results, with no post-injection delirium/sedation syndrome (PDSS) reported after 3,400+ injections, while meeting primary efficacy endpoints across all dosing groups with significant PANSS score improvements versus placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) unveiled its acceleration phase of "Pivot to Growth" strategy at its 2025 Innovation & Strategy Day. The company has achieved 9 consecutive quarters of growth and generated over $2.3 billion in revenue in 2024 from its innovative portfolio. Teva aims to build a $5+ billion innovative medicines franchise by 2030, led by AUSTEDO®, AJOVY®, and UZEDY®. Key targets include AUSTEDO sales exceeding $3 billion by 2030 and LAI schizophrenia franchise reaching $1.5-2.0 billion in peak sales. The company's late-stage pipeline includes promising assets like duvakitug (potential $2-5B peak sales) and DARI (~$1B potential). Teva reaffirmed its 2027 financial targets, including 30% operating margin, $2.7+ billion free cash flow, and plans for $700 million in net savings through organizational modernization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) has received Fast Track designation from the FDA for TEV-53408, an anti-IL-15 antibody being developed for celiac disease treatment. The drug candidate is currently in Phase 2a trials evaluating its efficacy and safety in adult celiac patients on a gluten-free diet. TEV-53408 works by inhibiting interleukin-15 (IL-15) to prevent intestinal damage and associated symptoms. The Fast Track status highlights the treatment's potential and the significant unmet medical need in celiac disease, which affects approximately 1% of the global population. This development demonstrates Teva's commitment to expanding its innovative pipeline in immunological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced upcoming presentations by its executive management team at two major healthcare conferences in June 2025. At the Jefferies Global Healthcare Conference on June 4, EVP U.S. Commercial Chris Fox and EVP Global R&D and Chief Medical Officer Dr. Eric Hughes will present at 9:20 am ET. At the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, President & CEO Richard Francis will present at 8:00 am ET. Live webcasts will be available on Teva's Investor Relations website, with archived versions accessible within 24 hours after each presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical and Biolojic Design have initiated IND-enabling studies for BD9, a novel dual-specific multibody targeting both TSLP and IL-13 for treating atopic dermatitis and asthma. BD9 was developed using Biolojic's Multibody Platform, which creates antibodies capable of addressing multiple disease targets simultaneously. The therapy aims to improve outcomes for patients with TH2-driven inflammatory diseases where current treatments are inadequate. This development aligns with Teva's Pivot to Growth strategy to enhance innovation in their pipeline. Under the agreement, Teva holds worldwide development rights for BD9, while Biolojic is eligible for milestone payments based on pre-clinical, clinical, regulatory, and commercial achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical (NYSE: TEVA) has announced an increase in its debt tender offer from $2.0 billion to $2.25 billion. The company is also raising the Pool Tender Caps for Pool 2 Notes and Pool 3 Notes from $250 million to $350 million each. This follows Teva's successful pricing of approximately $2.3 billion in senior notes on May 20, 2025. The tender offer includes multiple series of notes with varying interest rates and maturities, structured in three pools. Pool 1 has a maximum amount of $1.55 billion, while Pool 2 and Pool 3 each have a cap of $350 million. The offer expires on June 17, 2025, with an Early Tender Time of June 2, 2025. Holders who tender by the Early Tender Time will receive the Total Consideration, which includes an Early Tender Premium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
Rhea-AI Summary
Teva Pharmaceutical has successfully upsized and priced approximately $2.3 billion in senior notes, increased from the previously announced $2 billion. The notes consist of: €1 billion of 4.125% EUR-denominated notes maturing in 2031, $500 million of 6.000% USD-denominated notes maturing in 2032, and $700 million of 5.750% USD-denominated notes maturing in 2030. The proceeds will be used to fund tender offers for existing notes and repay outstanding debt. The settlement is expected around May 28, 2025. The notes will be unsecured senior obligations guaranteed by Teva and were offered through their shelf registration statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
FAQ
What is the current stock price of Teva Pharm (TEVA)?
The current stock price of Teva Pharm (TEVA) is $16.99 as of June 13, 2025.
What is the market cap of Teva Pharm (TEVA)?
The market cap of Teva Pharm (TEVA) is approximately 19.8B.
Teva Pharm
NYSE:TEVA
TEVA Rankings
TEVA Stock Data
19.78B
1.15B
0%
60.32%
2.43%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Israel
TEL AVIV